Empagliflozin vs Ipilimumab

Empagliflozin vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Empagliflozin and Ipilimumab.

Mechanism of Action

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Empagliflozin — 12.4 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7.

Molecular Weight: Empagliflozin — 450.9100 g/mol.

Type: Empagliflozin — Small molecule; Ipilimumab — Antibody.